microDimensions GmbH successfully closes seed round
March 7, 2014
MicroDimensions GmbH has recently closed a seed round: Convinced by the already successful product placement as well as the market potential for software solutions in digital pathology, High-Tech Gruenderfonds (HTGF), Bayern Kapital and business angel Dr. Adriaan Hart de Ruijter invested into the company specializing in microscopic image processing. The new capital allows microDimensions to accelerate the development of further products and the growth of the company.
MicroDimensions GmbH specializes in software solutions for digital pathology. The company’s innovative technology makes it possible to generate new findings in research and diagnostics by automatic combination of multiple microscopic images. Users in the development of medical agents or in pathology research benefit from microDimensions’ products as they allow them to reduce study costs and make quantitatively more accurate statements.
“We are very proud of having found, together with HTGF and Bayern Kapital, an internationally acclaimed private investor for microDimensions in the current development phase of our company,” says Dr. Martin Groher, CEO and co-founder of microDimensions GmbH. “Not only the funds, but also our investors’ expertise will help us tackle the next strategic steps rapidly, realize the development of new products in the near future and create new application possibilities for our customers in the fields of pathology and radiology.”
“MicroDimensions positions itself on the market for digital pathology with an attractive and innovative software solution which, as a platform, offers an attractive growth potential at the same time. We are very pleased to be able to support the company’s further development with the funding,” adds Ron Winkler, investment manager at High-Tech Gruenderfonds.
“We are convinced that thanks to the highly competent team and the interdisciplinary advisory council, microDimensions will soon be able to expand their share in the market for digital pathology,” says Brigitte Linseis, senior investment manager at Bayern Kapital. “With the product for 3D reconstruction of histological sections, microDimensions can make a contribution to pathology research, thus following the trend towards personalized medicine.”
About microDimensions GmbH
MicroDimensions GmbH is based in Munich and was founded in 2011 by Dr. Marco Feuerstein, Dr. Martin Groher and Dr. Hauke Heibel as a spin-off of the chair for Computer Aided Medical Procedures of the Technische Universität München (TUM). After a successfully completed project phase, as soon as 2012 the first customers could benefit from microDimensions’ software solutions. In a very early stage of its history, the company could already achieve first sales, together with the European market leader for “Virtual Slide Scanner”, 3DHISTECH Ltd., Hungary, since 2012 distribution partner of microDimensions.
With microDimensions’ first product “Voloom”, accurate 3D reconstructions can be generated from previously sectioned microscopic samples and then analyzed. For this purpose several sections are reconstructed to a high-resolution volume using a technology developed by microDimensions. This reconstruction is evaluated by means of algorithmic methods so that deformations in the extremely thin sections can be detected and compensated. The resulting 3D volume has a maximum analogy with regard to the unsectioned tissue samples. Compared to other software solutions, microDimensions’ solution has two decisive advantages. On the one hand, the reconstruction is generated automatically which significantly saves labour and time, as opposed to the semi-automatic procedures currently available. On the other hand, the microDimensions technology offers a maximum analogy with regard to the original sample; other section reconstruction methods cannot guarantee this result and are therefore less accurate.
About Bayern Kapital
Bayern Kapital was founded in 1995 on the initiative of the Bavarian State Government in the context of the “Bavarian Future Initiative” (Offensive Zukunft Bayern) in order to provide venture capital in particular for young innovative Bavarian companies. So far, Bayern Kapital has invested around 191 million euros in 220 innovative high-tech companies. Bayern Kapital is the regional contact and currently manages a total fund volume of about 200 million euros.
About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 573.5 million under management in two funds (EUR 272 million HTGF I, EUR 301.5 million HTGF II).
High-Tech Gruenderfonds Management GmbH
Phone: +49 (228) 823 001-00
Fax: +49 (228) 823 000-50